Gotrade News - SI-Bone (SIBN) reported third-quarter 2026 revenue of $55.7 million, up 14.5% from a year earlier, a net loss of $3.6 million, or $0.08 per diluted share, and reaffirmed its 2026 revenue guidance, according to the company's official release filed with the SEC on Monday, November 2, 2026.
SIBN Market Data
| Ticker | Close | Daily change | Market cap |
|---|
| SIBN | $20.22 | -4.76% | $906 million |
Regular-session close on November 2, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
SI-Bone Earnings Details
Worldwide revenue was $55.7 million for the quarter ended September 30, 2026, a 14.5% increase from $48.7 million in the same period of 2025, the company said. U.S. revenue rose 13.9% to $52.8 million from $46.4 million, and international revenue rose 27.0% to $2.9 million from $2.3 million. According to the release, U.S. revenue benefited from approximately 19.5% growth in procedure volume, partially offset by a lower average selling price due to procedure mix.
Gross margin was 79.3%, compared with 79.8% a year earlier. Operating expenses increased 9.7% to $48.5 million, while the operating loss improved by 19.2% to $4.4 million from $5.4 million. Net loss improved by 20.7% to $3.6 million, or $0.08 per diluted share, from $4.6 million, or $0.11 per diluted share, in the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was $3.0 million, up from $2.3 million, and cash from operations was $5.9 million. Cash and equivalents stood at $146.3 million as of September 30, 2026, compared with $145.9 million as of June 30, 2026.
Why It Matters for SIBN
The release compares the updated outlook with the guidance SI-Bone issued on August 3, 2026. The company kept its 2026 revenue guidance at $231 million to $233 million, approximately 15-16% growth, and its gross margin guidance at approximately 79.0%. Based on its year-to-date operating expense trend, it lowered its expected operating expense growth to approximately 10.5% at the revenue midpoint, from approximately 12.0%, and left its adjusted EBITDA guidance unchanged.
The company linked the quarter to its physician base and products. It reported 1,770 active U.S. physicians, growth of about 16%, and said new MS-DRGs for complex spinal fusion procedures using iFuse Bedrock Granite took effect in October, increasing average hospital inpatient payments by up to about $50,000 per qualifying procedure. "Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technologies," Chief Executive Officer Laura Francis said in the release.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Sources
